Global Pre-Implantation Genetic Diagnosis (PGD) Market

MARKET SCOPE:

The global Pre-Implantation Genetic Diagnosis (PGD) market is projected to grow significantly, registering a CAGR of 10.4% during the forecast period (2024 – 2032).

Preimplantation Genetic Diagnosis (PGD) is a specialized genetic testing method utilized alongside in vitro fertilization (IVF) to examine the genetic composition of embryos before their implantation in the uterus. The primary objective of PGD is to pinpoint genetic abnormalities or specific genetic conditions in embryos, enabling the selection and transfer of embryos devoid of the targeted genetic defects. The process is typically integrated into the IVF procedure, where eggs are retrieved from the ovaries and fertilized with sperm in a laboratory, resulting in the formation of embryos. Following fertilization, the embryos undergo cultivation and development over several days, with monitoring occurring until they reach a specific developmental stage, often the blastocyst stage. At this point, a small number of cells are extracted from each embryo for genetic testing, commonly performed on either the third day (cleavage stage) or the fifth day (blastocyst stage) of embryo development. The genetic material extracted from each embryo is then subjected to testing through various techniques, including polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and more recently, next-generation sequencing (NGS). These methodologies enable the identification of specific genetic mutations, chromosomal abnormalities, or single-gene disorders.

MARKET OVERVIEW:

Driver: The advancement in the diagnostic procedures in gene testing is predicted to foster the market growth.

Recent advancements in genomics research signal a shift from traditional monogenic genetics toward a comprehensive examination of the entire human genome. This transition involves the integration of massively parallel sequencing approaches and advanced bioinformatics. Presently, the capabilities extend beyond the original medical indication for which a patient and their family were referred for genetic testing, allowing the elucidation of single nucleotide variation (SNV), copy number variation (CNV), and structural variation (SV) in the entire human genome. Technological progress is evident in various applications such as expanded carrier screening (ECS), the end of gamete donor anonymity, preimplantation genetic testing (PGT), non-invasive prenatal testing (NIPT), and a deeper understanding of the root causes of male and female infertility.

Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening (PGD/PGS) have witnessed increased prevalence in in vitro fertilization (IVF) clinics, aiding numerous patients in achieving healthy pregnancies. The rapid evolution of biotechnologies has led to the development of new methods aimed at minimizing the negative impact on embryo development while enhancing the accuracy and efficiency of PGD/PGS. Simultaneously, non-invasive sampling methods, including time-lapse imaging technology, BF sampling, and cell-free nucleic acid collection, have been introduced into the field.

Opportunities: Use of fertility treatment options by single parents and same-sex couples is expected to pave the way for market growth in the upcoming years.

Laws endorsing the legalization of same-sex marriages have been implemented across various countries globally, signifying a substantial shift in societal perspectives and legal frameworks. This transformative trend, observed in nations like Greenland, Ireland, Canada, South Africa, and the United States, is expected to significantly influence the adoption of fertility procedures. These legal advancements underscore a more inclusive approach to family-building and reproductive rights, particularly for individuals in same-sex relationships and those who are single. For instance, in the Australian state of New South Wales, the Assisted Reproductive Technology Act 2007 has been enacted to permit all women, regardless of their marital status, to avail themselves of assisted conception procedures. This inclusive legislation ensures that single women and those in same-sex relationships have legal access to assisted reproductive technologies, including In Vitro Fertilization (IVF).

Similarly, in Western Australia, the Human Reproductive Technology Act 1991 allows all women, regardless of their sexual orientation or marital status (including lesbian or single women), to access donor insemination. This legal framework supports the reproductive rights of individuals, placing a strong emphasis on inclusivity in fertility treatments. These legal provisions signify a broader acknowledgment of diverse family structures and underscore the rights of same-sex couples and single individuals to pursue parenthood through assisted reproductive technologies. By eliminating discriminatory restrictions based on marital status or sexual orientation and granting access to fertility procedures, these laws contribute to fostering a more equitable and inclusive landscape within reproductive healthcare.

COVID IMPACT:

The global preimplantation genetic diagnosis market experienced a moderate impact during the COVID-19 pandemic. The extent to which the pandemic influenced the decision of pregnant women to undergo prenatal genetic tests remains unclear. The healthcare systems responded swiftly and extensively to the virus, implementing telehealth as a crucial component of these changes to minimize the risk of viral exposure among patients, healthcare providers, and communities. Due to the potential impact of COVID-19 on maternal and neonatal outcomes, along with the significance of prenatal genetic testing for ensuring high-quality prenatal care, various diagnosis and testing procedures were either postponed or delayed. Simultaneously, a prevailing fear of infection among individuals contributed to the reluctance to pursue these procedures. Consequently, the preimplantation genetic diagnosis market was only partially affected by the consequences of the COVID-19 pandemic.

SEGMENTATION ANALYSIS:

The Aneuploidy segment is anticipated to grow significantly during the forecast period.

Aneuploidy is a genetic disorder characterized by an abnormal number of chromosomes, wherein a human cell may possess 45 or 47 chromosomes instead of the usual 46. The rising prevalence of aneuploidy and the advancements in its diagnosis are anticipated to propel the preimplantation genetic diagnosis market. Trisomies, which involve an additional chromosome, are the most common form of aneuploidies in humans, constituting approximately 0.3% of live births. Trisomies typically result in a total of 47 chromosomes and, with few exceptions, are often incompatible with life, contributing to about 35% of spontaneous abortions.

To address the challenges associated with aneuploidy, particularly in improving live birth rates and reducing early pregnancy failure rates, preimplantation genetic testing-aneuploidy (PGT-A) has been introduced. Originally employing fluorescence in situ hybridization, which had limitations in assessing only a few chromosomes, PGT-A has evolved to encompass the evaluation of all chromosomes. Techniques such as array comparative genomic hybridization and next-generation sequencing are now utilized for comprehensive chromosomal analysis.

PGT-A serves as a valuable method to screen embryos for whole-chromosome abnormalities, aiding in the selection of embryos for transfer. In the past, embryo selection for transfer was primarily based on morphologic criteria, yet many women experienced unsuccessful pregnancies despite the transfer of morphologically optimal embryos. The expanded capabilities of PGT-A, now able to assess all chromosomes, provide a more thorough and precise screening process before embryo transfer, contributing to advancements in reproductive technologies.

The reagents and consumables segment is anticipated to grow significantly during the forecast period.

The growth of the reagents and consumables segment is propelled by the expanding applications of specific technologies, including Next-Generation Sequencing (NGS) and array Comparative Genomic Hybridization (aCGH) for whole-genome sequencing, as well as Fluorescence In Situ Hybridization (FISH) in the diagnosis of specific genetic disorders. Additionally, the increasing number of preimplantation genetic diagnosis and preimplantation genetic screening procedures conducted across major global markets contributes to the positive trajectory of this segment.

REGIONAL ANALYSIS:

The North America region is set to witness significant growth during the forecast period.

The presence of advanced healthcare facilities in this region is anticipated to propel market growth during the forecast period. Pre-implantation genetic diagnosis (PGD) is a service provided by more than 75% of fertility clinics in the United States, with its utilization in 4–6% of in vitro fertilization (IVF) procedures annually. While Preimplantation Genetic Screening (PGS) is effective in screening for aneuploidy in IVF patients, PGD is frequently employed for screening specific genetic disorders.

In 2018, a total of 306,197 Assisted Reproductive Technology (ART) cycles were conducted in the United States, resulting in approximately 73,831 live births. The advent of ART procedures has led to the birth of over one million babies in the country. Notably, 33% of IVF mothers achieve pregnancy during their initial cycle. The increasing prevalence of IVF procedures is anticipated to contribute to the market growth of the preimplantation genetic diagnosis market.

COMPETITIVE ANALYSIS

The global Pre-Implantation Genetic Diagnosis (PGD) market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.

Agilent Technologies, Inc.

• In October 2018, Agilent Technologies Inc. introduced Agilent OnePGT, an advanced genome-wide Next-Generation Sequencing (NGS) solution designed for preimplantation genetic testing (PGT).

Illumina, Inc.

Thermo Fisher Scientific Inc.

Perkinelmer, Inc.

Coopersurgical, Inc. (A Subsidiary of the Cooper Companies, Inc.)

Abbott Laboratories

Natera, Inc.

Takara Bio Usa Holdings, Inc.

Yikon Genomics

Invicta Genetics

Scope of the Report

By Test Type

• Chromosomal Abnormalities
• Gender Selection
• X-Linked Diseases
• Aneuploidy
• Single Gene Disorders
• Others

By Product Type

• Reagents & Consumables
• Instruments
• Software & Services

By Region

• North America (the United States & Canada)
• Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
• Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa, and Latin America)

Key reasons to purchase this report

It provides a technological development map over time to understand the industry’s growth rate and indicates how the Pre-Implantation Genetic Diagnosis (PGD) market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Pre-Implantation Genetic Diagnosis (PGD) submarket will be the main driver of the overall market from 2024 to 2032.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032. Show more